Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Erytech Pharma SA

Latest From Astellas Pharma US Inc.

Antibiotic Development: ‘Wildcard Exclusivity’ Proposal Returns

Economic ‘pull’ incentives that don’t require direct government spending draw support from industry and academic stakeholders.

United States BioPharmaceutical

Execs On The Move, September 2016

Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

BioPharmaceutical Medical Device

JPM15: Partnerships Important For Astellas’s Growth

With more than half of its research and development programs originating from partners, Astellas's pipeline reflects the company's commitment to growth through collaboration and the hunt for external innovation continues for both early and later-stage assets.

BioPharmaceutical United States

'Slam dunk' for Astellas antifungal Cresemba at FDA panel

Astellas had few battles to wage on 22 January when it took its experimental antifungal Cresemba (isavuconazonium) before the U.S. FDA's Anti-Infective Drugs Advisory Committee (AIDAC), which wholeheartedly embraced the medicine as a treatment for the deadly invasive infection aspergillosis, and nearly so for use in another fungal infection, mucormycosis.

BioPharmaceutical United States
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • Erytech Pharma SA
  • Senior Management
  • Gil Beyen, CEO
    Eric Soyer, CFO & COO
    Yann Godfrin, PhD, CSO
    Iman El-Hariry, MD, PhD, CMO
  • Contact Info
  • Erytech Pharma SA
    Phone: 4 78 74 44 38
    60 avenue Rockefeller
    Bâtiment Adénine, 69008